Back to results
US 2026/0158178 A1Published application
19f magnetic resonance imaging agents and methods of using thereof
AssigneeKuva Labs Inc.
InventorsAndrew Hopkins, Thomas Hopkins
Life of this patent
Estimating the term…
Abstract
Pharmaceutical compositions containing 19F-containing polymers and methods of using thereof for imaging applications are described herein. Systems and kits containing such pharmaceutical compositions are also described. For instance, the 19F-containing polymers can be used to image a target tissue and may be used analyze the size, shape, position, and/or the composition of the target tissue and/or to treat a disease or condition.
Claims29
A 19F-containing polymer comprising:
- a polymer backbone formed of a plurality of polymer repeat units;
- wherein at least about 1% and up to 99% of the polymer repeat units of the plurality comprise one or more 19F-atoms or 19F-containing groups covalently associated thereto;
- and
- wherein the 19F-containing polymer is hydrophilic and is soluble or substantially soluble in one or more pharmaceutically acceptable carriers.
1 more element
A 19F-containing polymer comprising:
- a polymer core comprising a plurality of arms, wherein each arm comprises a plurality of polymer repeat units;
- wherein at least about 1% and up to 99% of the polymer repeat units of the plurality comprise one or more 19F-atoms or 19F-containing groups covalently associated thereto;
- and
- wherein the 19F-containing polymer is hydrophilic and is soluble or substantially soluble in one or more pharmaceutically acceptable carriers.
1 more element
(canceled)
19-20. (canceled)
A pharmaceutical composition comprising:
- a plurality of the 19F-containing polymers, wherein each polymer of the plurality comprises a polymer backbone formed of a plurality of polymer repeat units, wherein at least about 1% and up to 99% of the polymer repeat units of the plurality of polymer repeat units comprise one or more 19F-atoms or 19F-containing groups covalently associated thereto, and wherein the polymer is hydrophilic;
- and
- one or more pharmaceutically acceptable carriers;
- wherein the plurality of the 19F-containing polymers are solubilized or substantially solubilized in the one or more pharmaceutically acceptable carriers.
1 more element
(canceled)
A method of imaging a target tissue in a subject, the method comprising the steps of:
- (i) administering a pharmaceutical composition to the subject, the pharmaceutical composition comprising:
- a plurality of the 19F-containing polymers, wherein each polymer of the plurality comprises a polymer backbone formed of a plurality of polymer repeat units, wherein at least about 1% and up to 99% of the polymer repeat units of the plurality of polymer repeat units comprise one or more 19F-atoms or 19F-containing groups covalently associated thereto, and wherein the polymer is hydrophilic;
- and
- one or more pharmaceutically acceptable carriers;
- wherein the plurality of the 19F-containing polymers are solubilized or substantially solubilized in the one or more pharmaceutically acceptable carriers;
- (ii) allowing an effective period of time for the plurality of the 19F-containing polymers of the pharmaceutical composition to accumulate in the target tissue of the subject;
- and
- (iii) imaging by 19F magnetic resonance imaging the plurality of the 19F-containing polymers following step (ii);
- wherein the imaging permits visualizing the target tissue and optionally may be used to analyze size, shape, position, and composition of the target tissue.
6 more elements
A system comprising:
- a pharmaceutical composition comprising:
- a plurality of the 19F-containing polymers, wherein each polymer of the plurality comprises a polymer backbone formed of a plurality of polymer repeat units, wherein at least about 1% and up to 99% of the polymer repeat units of the plurality of polymer repeat units comprise one or more 19F-atoms or 19F-containing groups covalently associated thereto, and wherein the polymer is hydrophilic;
- and
- one or more pharmaceutically acceptable carriers;
- wherein the plurality of the 19F-containing polymers are solubilized or substantially solubilized in the one or more pharmaceutically acceptable carriers;
- and
- a targeting composition comprising:
- a plurality of agents for targeted delivery of the plurality of the 19F-containing polymers of the pharmaceutical composition to a target tissue in a subject.
5 more elements
(canceled)
A method of imaging a target tissue in a subject, the method comprising the steps of:
- (i′) administering a system to the subject, wherein the system comprises:
- a pharmaceutical composition comprising:
- a plurality of the 19F-containing polymers, wherein each polymer of the plurality comprises a polymer backbone formed of a plurality of polymer repeat units, wherein at least about 1% and up to 99% of the polymer repeat units of the plurality of polymer repeat units comprise one or more 19F-atoms or 19F-containing groups covalently associated thereto, and wherein the polymer is hydrophilic;
- and
- one or more pharmaceutically acceptable carriers;
- wherein the plurality of the 19F-containing polymers are solubilized or substantially solubilized in the one or more pharmaceutically acceptable carriers;
- and
- a targeting composition comprising:
- a plurality of agents for targeted delivery of the plurality of the 19F-containing polymers of the pharmaceutical composition to a target tissue in a subject;
- (ii′) allowing an effective period of time for the plurality of the 19F-containing polymers of the pharmaceutical composition to accumulate in a target tissue of the subject;
- and
- (iii′) imaging by 19F magnetic resonance imaging the plurality of the 19F-containing polymers following step (ii′);
- wherein the imaging permits visualizing the target tissue and optionally may be used to analyze size, shape, position, and composition of the target tissue.
10 more elements
(canceled)
A method of treating or ameliorating a disease in a subject in need thereof, the method comprising the steps of:
- (a) administering a pharmaceutical composition, wherein the pharmaceutical composition comprises:
- a pharmaceutical composition comprising:
- a plurality of the 19F-containing polymers, wherein each polymer of the plurality comprises a polymer backbone formed of a plurality of polymer repeat units, wherein at least about 1% and up to 99% of the polymer repeat units of the plurality of polymer repeat units comprise one or more 19F-atoms or 19F-containing groups covalently associated thereto, and wherein the polymer is hydrophilic;
- and
- one or more pharmaceutically acceptable carriers;
- wherein the plurality of the 19F-containing polymers are solubilized or substantially solubilized in the one or more pharmaceutically acceptable carriers;
- and
- a targeting composition comprising:
- a plurality of agents for targeted delivery of the plurality of the 19F-containing polymers of the pharmaceutical composition to a target tissue in a subject;
- (b) allowing an effective period of time for the plurality of the 19F-containing polymers of the pharmaceutical composition to accumulate in a target tissue of the subject;
- and
- (c) imaging by 19F magnetic resonance imaging the plurality of the 19F-containing polymers following step (b);
- wherein the imaging permits visualizing the target tissue and optionally may be used to analyze size, shape, position, and composition of the target tissue;
- wherein the 19F-containing polymers comprise at least one active agent associated thereto selected from the group consisting of a therapeutic agent, a chemotherapeutic agent, a photosensitizer (such as IR700 or a phthalocyanine dye), and combinations thereof.
11 more elements
30-35. (canceled)
Dependencies are inferred from the claim text.